| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCRL1; FCRH1; IFGP1; IRTA5 |
| Entrez GeneID | 115350 |
| clone | 8F7F2 |
| WB Predicted band size | 47kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD307A (AA: extra 17-202) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD307A(FcRL5)抗体的3篇示例文献(注：文献为模拟生成，实际文献需通过学术数据库查询)：
1. **文献名称**: *"Targeting CD307A (FcRL5) with a Novel Antibody Enhances B-Cell Depletion in Chronic Lymphocytic Leukemia Models"*
**作者**: Smith A, et al.
**摘要**: 该研究开发了一种靶向CD307A的人源化单克隆抗体，证明其在体外和异种移植小鼠模型中可有效诱导慢性淋巴细胞白血病(CLL)细胞的凋亡，并增强现有化疗药物的疗效。
2. **文献名称**: *"CD307A as a Functional Marker for Regulatory B Cells in Autoimmunity"*
**作者**: Wang Y, et al.
**摘要**: 研究发现CD307A在调节性B细胞(Breg)中高表达，通过特异性抗体阻断CD307A信号通路，可加剧小鼠自身免疫性疾病，提示其在免疫调节中的关键作用。
3. **文献名称**: *"Structural Insights into CD307A Antibody Binding and Its Therapeutic Potential in Lupus Nephritis"*
**作者**: Gonzalez R, et al.
**摘要**: 通过冷冻电镜解析了CD307A与其治疗性抗体的复合物结构，揭示了结合表位特征，并在狼疮肾炎小鼠模型中验证了该抗体减少肾脏炎症和蛋白尿的效果。
如需具体文献，建议通过 **PubMed** 或 **Google Scholar** 检索关键词“CD307A antibody”或“FcRL5 therapeutic”获取最新研究。
CD307A, also known as FCRL5 (Fc receptor-like 5), is a transmembrane protein belonging to the Fc receptor-like family, which shares structural homology with classical Fc receptors but lacks direct Fc-binding capacity. It is primarily expressed on B lymphocytes, particularly memory B cells and plasma cells, and plays a regulatory role in B cell activation, differentiation, and immune response modulation. CD307A contains immunoreceptor tyrosine-based activation (ITAM) and inhibition (ITIM) motifs, suggesting dual signaling functions in balancing B cell receptor (BCR)-mediated signals.
Research highlights its involvement in autoimmune diseases and B cell malignancies. Elevated CD307A expression has been observed in conditions like rheumatoid arthritis and systemic lupus erythematosus (SLE), where it may contribute to pathogenic autoantibody production. In B cell cancers, such as chronic lymphocytic leukemia (CLL), CD307A serves as a potential diagnostic marker and therapeutic target due to its restricted expression on malignant cells.
CD307A-targeting antibodies are being explored for therapeutic applications, including antibody-drug conjugates (ADCs) or chimeric antigen receptor (CAR) T-cell therapies, leveraging its cell-surface specificity to minimize off-target effects. Its unique expression profile and regulatory mechanisms continue to make CD307A a focus of immunology and oncology research, offering insights into B cell biology and precision treatment strategies.
×
